The monarch butterfly – known as the “king of butterflies” – is one of the most recognizable and adored insects. But did you know they are as important to our environment as they are beautiful? Continue reading “Enter for your chance to win a free Monarch Butterfly Kit”
Five #BayerHawaii employees joined a dozen volunteers from Hawaii’s agricultural community on Monday, May 18 to bag and box more than 20,000 pounds of produce. It was part of the ‘Farm to Hospital’ program, created to help Oahu farmers and healthcare workers during the Covid-19 pandemic.
The Bayer Hawaii volunteers gathered at the Neal Blaisdell Exhibition Hall; it took the group seven hours to get the produce ready for delivery. In all more than 2,000 healthcare workers were treated to a bag full of pineapples, cabbage, papaya, sweet potatoes, and tomatoes.
Mahalo to the Hawaii Crop Improvement Association (HCIA) for putting the ‘Farm to Hospital’ event together along with other sponsors the Hawaii Farm Bureau, Healthcare Association of Hawaii, Hawaiian Electric, Simplot and Ulupono Initiative.
Bayer Hawaii is a member of HCIA.
Pacific Business News has more on this wonderful program:
The latest edition of our Hawaii community newsletter is now available. Due to the coronavirus situation, we are not mailing printed copies at this time. Instead, we hope you’ll enjoy this digital version which offers news stories about what we’ve been up to on the farm and in the community.Spring 2020 Newsletter
Click HERE to download or print the Spring 2020 newsletter now.
Our new vision, “Health for all, hunger for none”, sets the foundation for our future and serves as the mark by which we measure all activity across our company.
Our new vision, “Health for all, hunger for none”, sets the foundation for our future and serves as the mark by which we measure all activity across our company. Of course, the goal of “Health for all, hunger for none” will not be achieved overnight – particularly not in a time when hospitals are working at their limits and supply chains are under pressure in many places. However, we at Bayer are convinced that with our scientific expertise and innovative strength, we can make a significant contribution to ensuring that one day this vision becomes reality.
Already more than 100,000 of our employees around the globe are working very hard to bring our vision to life. With our products and services, we help to prevent, alleviate, and even cure diseases. At the same time, we are making an important contribution to a reliable supply of high-quality food and the responsible use of natural resources.
During the current crisis, we are also living up to our responsibility. We are in constant contact with governments, health authorities, charitable organizations and hospitals worldwide to provide concrete and pragmatic support on the ground. From medicines and donations of materials, to our know-how and manpower and urgently needed financial assistance. You can find more information about our contribution to the fight against COVID-19 here. I also spoke about this yesterday at our AGM, which you can view here.
I am convinced that the current challenges emphasize the importance of pursuing ambitious goals as articulated in our vision. Why? I would like to explain this briefly here.
1) Health and nutrition are system critical
COVID-19 has changed the way we look at the world. Suddenly, almost every conversation ends with the words “stay healthy”, or “stay safe”. For the first time in history, many people in developed countries have experienced what it is like to find themselves in front of empty supermarket shelves.
Suddenly, almost every conversation ends with the words “stay healthy”, or “stay safe”.
This has shown people, how crucial the health and nutrition sectors are – in times of COVID-19, but of course also beyond. The current situation also shows how important it is that both areas are managed responsibly, across both the public and private sectors. It therefore makes me proud that Bayer is a global leader in these two sectors, and we have an important part to play.
2) Progress needs science
Science is the foundation for making decisive and urgently needed progress in the fields of health and nutrition. If, a few years ago, this statement would have been dismissed as rather obvious or trivial, it is now more relevant than ever – particularly when it occasionally feels that the opinion of a next-door neighbor is given more attention than rigorous scientific investigation.
With COVID-19 we are seeing scientists become the new rock stars with society turning to them for hope.
Often, we are seeing that facts are accepted only if they fit into one’s own world view. Now, with COVID-19, we are seeing scientists become the new rock stars with society turning to them for hope. It is becoming clearer to people that without science, we have no chance of fighting the virus. Consequently, the advice of scientists is being listened to again. Whether as advisors to governments, in hospitals or in the development of vaccines, the experts have an important voice again, and that is a good thing.
Science and research play a central role at Bayer.
I sincerely hope that this development will be sustained. After all, science and research play a central role at Bayer. More than 16,000 of our colleagues are working in Research and Development. Last year, we spent €5.3 billion on R&D, more than ever before. We are well aware: Such an ambitious project as “Health for all, hunger for none” can only succeed through innovation.
3) Global challenges require global solutions
In recent weeks, we have seen how the importance of supplying basic goods and services has come to the fore globally. This is not about luxury products for a few, but about basic access to health and nutrition for as many people as possible worldwide.
Global challenges can best be solved if we act in solidarity. This view is also reflected in our sustainability goals.
COVID-19 clearly shows that global challenges can be solved if we act in solidarity, for example by states disclosing infection figures transparently and quickly, or by ensuring the movement of goods, particularly food, seamlessly across borders. This is also seen when research institutes share their findings on a global level, when companies refocus production on needed equipment like masks or respirators, or donate medicines, and when each individual follows rules that limit the further exponential spread of the disease.
We are convinced that an inclusive approach is essential not only in dealing with COVID-19, but also with other global challenges. This view is also reflected in our sustainability goals. With these goals we expressly commit ourselves to reaching several hundred million additional people.
“Health for all, hunger for none” – this vision will shape and drive Bayer forward in the coming years.
As schools remain closed due to the coronavirus pandemic, Bayer is offering free, educational resources for Hawaii’s families. Continue reading “Bayer Hawaii Releases Children’s Coloring Book about Hawaii’s Backyard Bugs”
The coronavirus presents the world with major challenges. “As a company active in the areas of health and nutrition, we can provide substantial help in overcoming the crisis with our products and our expertise,” says Werner Baumann, Chairman of the Board of Management. “Our employees are working round the clock to do just that.”
With the significant burden COVID-19 is having on the healthcare systems and increased need for self-care solutions, Bayer announced today a donation of one million products to support the health of underserved communities. Continue reading “Bayer to Donate One Million Over-the-Counter Products and Multivitamins to Americans In Need”
WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer today announced it is joining the U.S. Government’s fight against COVID-19 with a donation of 3 million tablets of the drug Resochin (chloroquine phosphate).
Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, also appears to have broad spectrum antiviral properties and effects on the body’s immune response. New data from initial preclinical and evolving clinical research conducted in China, while limited, shows potential for the use of Resochin in treating patients with COVID-19 infection.
Bayer in recent days has been in talks with the White House, HHS, CDC, and the FDA, offering any assistance we can provide with a focus on donating Resochin to help in the government’s efforts to combat the virus.
Currently not approved for use in the United States, Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Bayer thanks the Trump administration for moving quickly to enable this donation and will continue to work closely with the administration to support its efforts in the fight against COVID-19.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.us.
Social Media Channels
– Facebook: BayerUnitedStates
– Twitter: BayerUS
– Instagram: BayerUS
– YouTube: BayerUS
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005585/en/
Mobile: (973) 437-0809